FDA Approves Enhertu for Two HER2-Positive Early Breast Cancer Indications, Moving the AstraZeneca-Daiichi ADC Into Curative-Intent Treatment
AstraZeneca and Daiichi Sankyo's trastuzumab deruxtecan won simultaneous neoadjuvant and adjuvant approvals on May 15, backed by 927-patient DESTINY-Breast11 and 1,635-patient DESTINY-Breast05 Phase III trials.
5 min read7 sources